Loading...
The immunotherapy doublet of ipilimumab and nivolumab along with a variety of tyrosine kinase inhibitor (TKI)/immune checkpoint inhibitor combinations are standard-of-care options for patients with advanced clear cell renal cancer with intermediate or poor prognostic risk according to the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) index.
In an industry-sponsored phase 3 study, 855 previously untreated patients with advanced renal cancer with a clear-cell component and intermediate or poor IMDC prognostic risk were randomized to receive the standard renal dose and schedule of nivolumab and ipilimumab plus either the TKI cabozantinib (40 mg/day) or placebo. The primary end point was progression-free survival (PFS)…